Will Divi's business expansion boost its valuations?Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companie...
29 Jul, 2022, 11.32 AM IST
Gurmeet Chadha on top 3 new holdings in portfolio“Since we launched the PMS, the top new holdings in our portfolio include Reliance where we think what has happened to Jio would happen to ...
31 May, 2022, 02.42 PM IST
Abhay Agarwal on why he added Divi's, LTI and Lemon Tree to his portfolio now“There were some stocks that we always wanted to buy but we found them to be expensive. In this correction, we have got the opportunity to ...
21 Mar, 2022, 04.10 PM IST
Glenmark Life IPO kicks off: Here's what makes analysts bullish on the issueAnalysts are positive on the company's prospects, given that China Plus One strategy by global formulation makers -- to de-risk their procu...
27 Jul, 2021, 09.39 AM IST
India’s best-performing stock is seeing a wave of optimistic callsThe optimism is stemming from the company’s capacity-expansion plans and potential to win more business as India cuts its reliance on Chine...
13 Jan, 2021, 03.55 PM IST
Saurabh Mukherjea reveals his 3 favourite pharma stocksOver a two-three-year period, the pricing power in API space will ebb away and margins will come back down, says Saurabh Mukherjea.
04 Dec, 2020, 02.05 PM IST
What makes the latest pharma company to enter Nifty very different from its peers in the index?Unlike its peers, Divi is a pure-play active pharma ingredients (API) company and does not face the same challenges and risks as that of it...
27 Aug, 2020, 11.53 PM IST
Stocks in the news: Divi's Labs, SBI Life, ZEEL, IRCTC, Bharti Infratel, Hindalco and PNBThe dedicated bankruptcy court has decided to appoint an IRP in a case filed by lender State Bank of India (SBI) against Anil Ambani.
21 Aug, 2020, 10.21 AM IST
Buy Divi's Laboratories, target Rs 1,600: Axis CapitalBuy Divi's Laboratories Ltd. at a price target of Rs 1600.
05 Dec, 2018, 02.20 PM IST
Not biggies, go for these niche pharma cos: Dipan MehtaBuy contract manufacturing pharma companies on correction, says Mehta.
30 Aug, 2018, 10.43 AM IST
Neutral on Divi's Laboratories, target Rs 1200: Motilal OswalNeutral Divi's Laboratories Ltd. at a price target of Rs 1200.0 .
30 May, 2018, 10.08 AM IST
Divis to spend Rs 300 crore on expansion plans in 2018The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during th...
30 Jan, 2018, 04.56 PM IST
Top stocks in focus on Monday, 14 August 2017Here is a list of top stocks that are likely to be in focus in today's trading session.
14 Aug, 2017, 11.40 AM IST
Managing LAP, affordable home growth key for HFCsHowever, after a sharp jump in stock prices over the past year, valuations appear to be rich.
03 May, 2017, 10.39 AM IST
Divi's Labs: Short term pain, long term positiveThe stock of drug firm Divi's Labs has corrected 12% since the company announced its March quarter at the beginning of this week.
24 May, 2013, 07.44 PM IST
- Divis Labs will maintain stable growth momentum and benefit from weak rupee
The company is ahead of its peers in margin growth and has recorded a consistent revenue growth of above 30% for the past five quarters.
16 Apr, 2012, 08.55 AM IST
- Drug formulations pep up sector, but contract research spoils Q3 party
However, pharma companies mainly into formulations have managed to show strong growth, except for those who had operations in Germany and s...
03 Feb, 2010, 02.37 AM IST